The Future of Oncology Trials: Innovation & Genomic Profiling in Australia March 10th, 2021


Join the conversation with Susan Cole, George Clinical’s Global Head Therapeutic Strategy, Oncology, and Prof. David Thomas of the Garvan Institute of Medical Research, covering the future of oncology trials and genomic profiling.

Genomic profiling is changing cancer medicine, enabling mapping of the mutational circuitry of cancers. Dozens of highly effective therapies have changed treatment options for many cancers and have received regulatory approval. This evolution has driven the development of large-scale genomic profiling programs linked to biomarker-dependent therapeutic trials.

In Australia, a national precision oncology platform to enable large-scale genomic screening of cancer patients has been developed through an innovative non-profit company, Omico. George Clinical’s collaboration with Omico looks to harness the paradigm-shifting potential of this platform to change the way how oncology trials are conducted in Australia.

The webinar will also address:

  • An introduction to the Omico platform
  • Economic hurdles that can impact the way diagnostic algorithms and a standard of care are implemented
  • The potential of genomic profiling to revolutionize clinical trial access to and for patients
  • Operational barriers faced in the implementation of oncology trials and how these could be surpassed with a platform such as Omico


George Clinical's Scientific Leadership in Attendance

David Thomas

  • Director of The Kinghorn Cancer Center, CEO of the Australian Genomic Cancer Medicine Centre
  • Head of Cancer Research, Garvan Institute of Medical Research

Prof. David Thomas is the Director of The Kinghorn Cancer Centre and a NHMRC Principal Research Fellow at the Garvan Institute of Medical Research. As a clinician-scientist, his focus is on the application of genomic technologies to the understanding and management of cancer. Prof Thomas founded the Australasian Sarcoma Study Group, a national research organization, and established Australia’s leading adolescent and young adult cancer unit at the Peter MacCallum Cancer Centre. Dr Thomas leads the International Sarcoma Kindred Study, now recruiting from 23 centres in 7 countries, and led the first international study of denosumab in Giant Cell Tumor of bone, leading to FDA and TGA approval. Since moving to NSW, has established the Australian Genomic Cancer Medicine Centre t/as Omico, a national precision medicine program for patients with rare and early onset cancers.

Susan Cole

  • Global Head Therapeutic Strategy, Oncology
  • Regional Head of Project Operations USA & Europe

Susan is responsible for U.S. project and clinical operations, including project management, study startup, monitoring and site management services. With over 25 years in clinical research, she brings experience in all phases of clinical trials, multiple therapeutic areas including over 12 years in oncology, and key leadership roles in clinical operations and financial management. She has helped develop or improve services for multiple U.S. Contract Research and Site Management organizations, as well as a national oncology site network. Her work with global and cross-functional teams brings added value to the George Clinical team.

Event Location

Zoom Webinar

Attending this event?

Meet with George Clinical! Contact us to schedule a time now.

    Sign Up For Our Newsletter

    I wish to subscribe to George Clinical communications.

    Add George Clinical to your network